TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~• Participant has completed the treatment phase of their Core Studies: GWEP1332A \[NCT02091206\], GWEP1332B \[NCT02091375\], GWEP1424 \[NCT02224703\], GWEP1414 \[NCT02224560\], GWEP1424 \[NCT02224703\], and GWEP1423 \[NCT02224690\].~Key Exclusion Criteria:~* Participant is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to study entry other than the investigational medicinal product (IMP) received during the Core Study and are unwilling to abstain for the duration for the study.~* Any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at Visit 1.~* Participant has been part of a clinical trial involving an IMP during the inter-study period.~* Female participant is of child bearing potential or male participant's partner is of child bearing potential, unless willing to ensure that they or their partner use highly effective contraception, for example, hormonal contraceptives, intrauterine devices/hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence, during the study and for 3 months thereafter (however, a male condom should not be used in conjunction with a female condom).~* Participant has significantly impaired hepatic function at the 'End of Treatment' visit of their Core Study or at Visit 1 if re-assessed: i) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 × upper limit of normal (ULN); ii) ALT or AST \>3 × ULN and (total bilirubin \[TBL\] \>2 × ULN or international normalized ratio \[INR\] \>1.5); iii) ALT or AST \>3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (\>5%). This criterion must be confirmed prior to entering the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GWP42003-P (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polyprenols (Ropren) in Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute coronary syndrome~* Informed consent received~Exclusion Criteria:~* Patient's incapacity to take accurately drops by oneself~* Cardiogenic shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Group (Type: PLACEBO_COMPARATOR): Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
- Polyprenol Group (Type: EXPERIMENTAL): Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥40 years with COPD diagnosis according to the current GOLD (The Global Initiative for Chronic Obstructive Lung Disease) strategy.~* Patients who have symptomatic stable moderate to severe COPD diagnosis with post-bronchodilator FEV1/FVC ratio \<0.70, and FEV1 \<80% of predicted normal at screening visit.~* Current smokers or ex-smokers with a smoking history of at least 10 pack-years~* Patients who have no exacerbation within last 4 weeks~* Female patients with childbearing potential using effective birth control method~* Patients who signed written informed consent prior to participation~* Patients who accept to comply with the requirements of the protocol~* Patients who have a capability of communicate with investigator~Exclusion Criteria:~* History of hypersensitivity to drugs contains anticholinergics, beta-adrenergic, lactose~* Diagnosis of asthma~* Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening visit or during run-in period.~* Patients who had COPD exacerbation or lower respiratory track infections that required antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to screening visit or during run-in period.~* Patients who have a history of myocardial infarction, hearth failure, acute ischemic coroner disease or severe cardiac arrhythmia requiring treatment within least 6 weeks~* Patients who have lung cancer~* Patients with active tuberculosis~* Patients who use oxygen therapy~* Patients who have common interstitial lung diseases like cystic fibrosis, bronchiolitis obliterans~* Patients with serious liver or renal disease that leads to organ failure~* Women who are pregnant or nursing~* History of allergic rhinitis and atopy~* Known symptomatic prostatic hypertrophy requiring drug therapy or operation~* Patients with narrow-angle glaucoma requiring drug therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium/Formoterol (Type: EXPERIMENTAL): Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
- Tiotropium + Formoterol (Type: ACTIVE_COMPARATOR): Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection on second line treatment in the 2lady trial for at least 48 weeks~* VL ≤ 200 copies/ml since at least 6 months~* No change in ART in the last 3 months previous to the study~* CD4\> 100 cells/ml~* Signed informed consent~* Adherence \>90~Exclusion Criteria:~* Previous viral failure (at least 2 consecutive HIV RNA \>1000 copies/ml) while receiving a PI~* Ongoing pregnancy and breast feeding women~* HBsAg positive patients~* opportunistic infection or any severe or progressive disease ongoing or treated in the 3 months before screening~* Subject who in the investigator's opinion is unable to complete the study~* History or symptoms of HIV encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- monoPI - boosted lopinavir or boosted darunavir (Type: ACTIVE_COMPARATOR): boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96.
- bi therapy - (boosted lopinavir or darunavir) + lamivudine (Type: ACTIVE_COMPARATOR): boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling~* Age 65 and older~* Men and women of all ethnic groups~* Self-reported of provider-diagnosed with Type 2 Diabetes (T2D) for at-least 6 months.~* Received basic diabetes self-management education~* Stable medication regimen and no medication changes are expected over the next 6 months.~* Overweight/obese (Body Mass Index (BMI) ≥25 kg/m2~* Able to read and write in English~* Own a smartphone~* At PI discretion, participant is willing/able to comply with the protocol requirements~Exclusion Criteria:~* Unsafe to walk using Exercise Assessment and Screening for You (EASY) criteria or clinical judgement of the PI.~* History of severe psychiatric disorders or cognitive impairment which interferes with active participation in the study~* Residence of long-term care facility~* History of substance abuse in the past year~* Unwilling to be randomized in a Mobile Health (mHealth+) individual intervention group

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Behavioral Lifestyle Intervention (Type: EXPERIMENTAL): The participants will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
- Group B control arm (Type: OTHER): Participants use the smart-phone app to record their daily diet and physical activity, with no group sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telemedicine Outreach for Post Traumatic Stress in CBOCs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnostic Criteria for PTSD (CAPS),~* veterans,~* treated in CBOC~Exclusion Criteria:~* schizophrenia,~* bipolar disorder,~* current substance dependence,~* current specialty PTSD treatment at VA Medical Center,~* no access to telephone,~* hearing or speech impediment,~* terminal illness,~* non-capacity to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Telemedicine Outreach for PTSD (Type: EXPERIMENTAL): Telemedicine-Based Collaborative Care
- Arm 2 Treatment as usual (Type: NO_INTERVENTION): Usual Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Acute coronary syndrome (unstable angina, NSTEMI, and STEMI)~* Significant coronary artery stenosis (\>50% by visual estimate) eligible for coronary stenting~* Between 20 and 75 years of age~* Body weight ≥ 60kg~* Aspirin dose of 100 mg is recommended~* Ability to understand and to comply with the study protocol~Exclusion Criteria:~* Prior history of ischemic or hemorrhagic stroke or transient ischemic attack, or sub-arachnoids hemorrhage~* fibrinolytic or abciximab therapy within 48 hours of entry or randomization into the study~* vitamin K antagonist~* History of intolerance or allergy to ASA or approved thienopyridines (ticlopidine, clopidogrel, or prasugrel)~* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)~* active pathological bleeding or history of bleeding diathesis~* Thrombocytopenia (platelets \< 100,000/mm3)~* Severe hepatic impairment (Child Pugh class C).~* a condition associated with poor treatment compliance, including dementia or mental illness

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: ACTIVE_COMPARATOR): Fixed-dose Prasugrel of 10 mg/d
- group 2 (Type: ACTIVE_COMPARATOR): Fixed-dose Prasugrel of 5 mg/d
- group 3 (Type: ACTIVE_COMPARATOR): Phenotype-based prasugrel dose~* If patients show PRU \< 85, prasugrel dose will be reduced by 5 mg/d.~* If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary open-angle glaucoma~* Male or female at least 18 years of age and able to provide written informed consent~* Mean IOP (at baseline visit after washout of any medications) must be 22 mm Hg and no greater than 38 mm Hg~* Likely to be available and willing to attend follow-up visits~Exclusion Criteria:~* Angle closure glaucoma~* Secondary glaucomas~* Prior glaucoma procedures~* Elevated episcleral venous pressure from history of active thyroid orbitopathy, carotid-cavernous fistula, orbital tumors, or orbital congestive disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stent (Type: ACTIVE_COMPARATOR): One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
- Medication (Type: ACTIVE_COMPARATOR): One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Passy Muir Swallowing Self Training Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stroke or post radiation for the treatment of head and neck cancer~* Dysphagia with a score of 2 or greater on the Penetration/Aspiration Scale OR a Mann Assessment of Swallowing Ability ordinal risk rating of probable or definite~Exclusion Criteria:~* Neck injury~* Epilepsy~* Neurological disorder other than stroke~* Psychiatric illness other than depression~* Uncontrolled gastroesophageal reflux disease~* Inability to communicate secondary to significant speech or language problems~* Inability to maintain alertness for 1 hour~* Significant health concerns that would put the participant at risk

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vibrotactile Stimulation in Dysphagia (Type: None): A Vibrotactile stimulation device will be evaluated in patients with chronic moderate to severe dysphagia for more than 6 months post onset due to stroke or following radiation treatment for head and neck cancer to assess which frequency, mode, pressure characteristics are most helpful in increasing the rate of swallowing, increasing the urge to swallow, assisting with the initiation of swallowing and not affecting discomfort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Patients may be male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2. Patients must be HBeAg positive and have chronic hepatitis B with no history of clinical decompensation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NVR 3-778 (Type: EXPERIMENTAL): NVR 3-778 in varying doses of capsules by mouth for 28 days
- Placebo for NVR 3-778 (Type: PLACEBO_COMPARATOR): Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
- NVR 3-778 and Pegasys (Type: EXPERIMENTAL): NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
- Pegasys (Type: ACTIVE_COMPARATOR): Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Ages 18-75 years inclusive.~* Ability to comprehend the investigational nature of the study and provide informed consent.~* Thrombocytopenia (due to congenital causes, bone marrow failure, hematologic malignancies, and treatment related), defined as \<10k/uL without bleeding or \<30K/uL with evidence of life threatening bleeding (intracranial hemorrhage, GI bleeding, pulmonary hemorrhage, uncontrolled epistaxis, hematuria).~* Diagnosed with immune platelet refractoriness, characterized by all of the following:~  * Lack of adequate post-transfusion platelet count increment, defined by, CCI \<7500/ul at 10-60 min, and CCI \<5000/ul at 18-24 hrs (in those who had a CCI at 10-60 min greater than or equal to 5000/microl)after at least 2 consecutive transfusions.~ * Presence of anti-HLA class A and/or B antibody.~EXCLUSION CRITERIA:~* Active meningococcal infection.~* Severe psychiatric illness. Mental deficiency sufficiently severe as to make making informed consent impossible.~* Positive pregnancy test for women of childbearing age within 1 week.~* HIV positive test within 3 months~* Paroxysmal Nocturnal Hemoglobinuria (PNH) disease with evidence of intravascular hemolysis.~* Presence ITP/autoimmune thrombocytopenia~* Immune platelet refractoriness responsive to treatment with IVIG~RE-ENROLLMENT CRITERIA:~* Meet response criteria to the initial treatment or second treatment~* Meets all initial inclusion/exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): 1200 mg IV infusion over 30-40 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 2 to \<18 years old.~* Diagnosis of Gaucher disease with leukocyte acid β-glucosidase activity ≤30% of the mean of the reference range for healthy subjects.~* Subjects who have not received enzyme replacement therapy (ERT) in the past or who have not received ERT in the past 12 months and have a negative anti-glucocerebrosidase antibody assay.~* Subjects who have not received substrate reduction therapy (SRT) in the past 12 months.~* Subjects whose clinical condition, in the opinion of the investigator, requires treatment with enzyme replacement therapy (ERT).~Exclusion Criteria:~* Currently taking another investigational drug for any condition.~* Presence of neurological signs and symptoms characteristic of Gaucher disease with complex neuronopathic features other than longstanding oculomotor gaze palsy.~* Presence of unresolved anemia due to iron, folic acid, or vitamin B12 deficiency~* Previous hypersensitivity reaction to Cerezyme® (imiglucerase) or Ceredase® (alglucerase).~* History of allergy to carrots.~* Presence of HIV, HBsAg or hepatitis C infections.~* Subject's parent(s) or legal guardian(s) are unable to understand the nature, scope and possible consequences of the study.~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 30 units/kg (Type: EXPERIMENTAL): None
- 60 units/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete